Insulin Producing Stem Cell Transplantation Clinical Trial in Type 1 Diabetes

Type 1 Diabetes is a chronic autoimmune disease. It results from autoimmune destruction of pancreatic Beta cells leading to absolute insulin insufficiency. The establishment of pluripotent like human stem cells derived from adipose tissue derived mesenchymal cell origin have introduced a new potential source for cell therapy in type 1 diabetic patients, especially in light of recent successes in producing glucose-sensitive insulin secreting cells and this will be the scope of this study. In the last decade, human clinical trials of introducing insulin producing stem cells from various origins were approved and conducted.

NCT Number	NCT06951074
Lead Sponsor	Ain Shams University
Conditions	Stem Cells, Type 1 Diabetes
Enrollment	20 participants
Start Date	2025-04-01
Primary Completion	2026-05-01 (estimated)
Study Completion	2026-09-01 (estimated)
Updated on ClinicalTrials.gov	2025-04-30